The study of Choi et al did not identify any associations between MYD88 expression and clinicopathological variables such as stage or IPI score.[5] In contrast, the study of Caner et al found a reverse relationship between MYD88 overexpression and stage and IPI score.[1] In our research, we also analyzed MYD88 protein expression by IHC analysis in mature B-cell NHLs, and similar to the results reported by Choi et al and by Caner et al, our study failed to reveal the correlation between MYD88 mutation and expression. Here, MYD88 is linked to B-cell non-Hodgkin lymphoma.